EXEL Stock Forecast 2025-2026
Distance to EXEL Price Targets
EXEL Price Momentum
🤔 Considering Exelixis (EXEL)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Latest EXEL Stock Price Targets & Analyst Predictions
Based on our analysis of 29 Wall Street analysts, EXEL has a bullish consensus with a median price target of $38.50 (ranging from $23.00 to $45.00). The overall analyst rating is Buy (7.6/10). Currently trading at $36.65, the median forecast implies a 5.0% upside. This outlook is supported by 12 Buy, 9 Hold, and 1 Sell ratings.
The most optimistic forecast comes from David Lebowitz at Citigroup, projecting a 22.8% upside. Conversely, the most conservative target is provided by Sudan Loganathan at Stephens & Co., suggesting a 37.2% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
EXEL Analyst Ratings
EXEL Price Target Range
Latest EXEL Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for EXEL.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 13, 2025 | RBC Capital | Gregory Renza | Outperform | Maintains | $40.00 |
| Feb 24, 2025 | Wells Fargo | Derek Archila | Equal-Weight | Downgrade | $36.00 |
| Feb 13, 2025 | Barclays | Peter Lawson | Equal-Weight | Maintains | $29.00 |
| Feb 13, 2025 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $40.00 |
| Feb 12, 2025 | Guggenheim | Michael Schmidt | Buy | Reiterates | $42.00 |
| Feb 12, 2025 | Stifel | Stephen Willey | Hold | Maintains | $36.00 |
| Feb 12, 2025 | Stephens & Co. | Sudan Loganathan | Equal-Weight | Reiterates | $29.00 |
| Feb 12, 2025 | Citigroup | David Lebowitz | Buy | Maintains | $45.00 |
| Feb 12, 2025 | Piper Sandler | Joseph Catanzaro | Overweight | Maintains | $38.00 |
| Jan 28, 2025 | UBS | Ashwani Verma | Neutral | Maintains | $34.00 |
| Jan 27, 2025 | Truist Securities | Asthika Goonewardene | Buy | Maintains | $43.00 |
| Jan 27, 2025 | Morgan Stanley | Jefferson Harralson | Overweight | Upgrade | $40.00 |
| Jan 27, 2025 | JMP Securities | Silvan Tuerkcan | Market Outperform | Maintains | $41.00 |
| Jan 27, 2025 | Stephens & Co. | Sudan Loganathan | Equal-Weight | Reiterates | $29.00 |
| Jan 27, 2025 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $40.00 |
| Jan 24, 2025 | Oppenheimer | Jay Olson | Perform | Downgrade | $33.00 |
| Jan 23, 2025 | JMP Securities | Silvan Tuerkcan | Market Outperform | Reiterates | $41.00 |
| Jan 22, 2025 | Guggenheim | Michael Schmidt | Buy | Reiterates | $0.00 |
| Jan 16, 2025 | Oppenheimer | Jay Olson | Outperform | Maintains | $41.00 |
| Jan 15, 2025 | Truist Securities | Asthika Goonewardene | Buy | Maintains | $42.00 |
Exelixis Inc. (EXEL) Competitors
The following stocks are similar to Exelixis based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Exelixis Inc. (EXEL) Financial Data
Exelixis Inc. has a market capitalization of $10.26B with a P/E ratio of 20.8x. The company generates $2.17B in trailing twelve-month revenue with a 24.0% profit margin.
Revenue growth is +18.2% quarter-over-quarter, while maintaining an operating margin of +28.8% and return on equity of +23.1%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Exelixis Inc. (EXEL) Business Model
About Exelixis Inc.
Develops cancer treatment therapies.
Exelixis Inc. generates revenue through the commercialization of its cancer therapies, notably Cabometyx, which is used for treating advanced renal and liver cancers. The company also invests in a diverse pipeline of oncology projects, enhancing its product offerings and catering to unmet medical needs. Collaborations with other pharmaceutical companies further augment its research capabilities and market presence.
Founded in 1994, Exelixis is focused on oncology and aims to impact cancer management significantly. Its ongoing projects and partnerships position it as a key player in the biopharmaceutical sector, addressing critical healthcare challenges.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
1,147
CEO
Dr. Michael M. Morrissey Ph.D.
Country
United States
IPO Year
2000
Website
www.exelixis.comExelixis Inc. (EXEL) Latest News & Analysis
The top five biotech stocks currently share strong ratings, highlighting their positive market performance.
Strong ratings for top biotech stocks indicate potential for growth and stability, suggesting favorable investment opportunities in the sector.
Exelixis, Inc. (Nasdaq: EXEL) will present at the TD Cowen Health Care Conference on March 4 and the Barclays Global Healthcare Conference on March 11.
Exelixis's participation in major investor conferences highlights potential growth opportunities and can influence investor sentiment and stock performance.
Analysts are optimistic about Carpenter Technology and Exelixis, highlighting their positive outlook, which exceeds even that of Nvidia.
Positive analyst sentiment on Carpenter Technology and Exelixis may drive stock demand, indicating potential growth opportunities that could outperform major players like Nvidia.
Investors in Medical - Biomedical and Genetics stocks are assessing the attractiveness of Exelixis (EXEL) and Techne (TECH) for value investment opportunities.
The comparison between Exelixis and Techne highlights potential investment opportunities in the biomedical sector, influencing stock selection strategies for value investors.
Four PEG-based GARP investment picks identified are Gilead Sciences (GILD), Exelixis (EXEL), Synchrony Financial (SYF), and Molson Coors Beverage Company (TAP).
PEG-based GARP picks indicate potential for growth at a reasonable price, suggesting these stocks may offer attractive investment opportunities with balanced risk and reward.
Exelixis (EXEL) shares rose 5% on Friday after the company announced a significant move favorable to shareholders, attracting increased market interest.
Exelixis's stock surge indicates strong market confidence, likely driven by positive news or strategic moves, which could signal growth potential and attract further investment interest.
Frequently Asked Questions About EXEL Stock
What is Exelixis Inc.'s (EXEL) stock forecast for 2025?
Based on our analysis of 29 Wall Street analysts, Exelixis Inc. (EXEL) has a median price target of $38.50. The highest price target is $45.00 and the lowest is $23.00.
Is EXEL stock a good investment in 2025?
According to current analyst ratings, EXEL has 12 Buy ratings, 9 Hold ratings, and 1 Sell ratings. The stock is currently trading at $36.65. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for EXEL stock?
Wall Street analysts predict EXEL stock could reach $38.50 in the next 12 months. This represents a 5.0% increase from the current price of $36.65. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Exelixis Inc.'s business model?
Exelixis Inc. generates revenue through the commercialization of its cancer therapies, notably Cabometyx, which is used for treating advanced renal and liver cancers. The company also invests in a diverse pipeline of oncology projects, enhancing its product offerings and catering to unmet medical needs. Collaborations with other pharmaceutical companies further augment its research capabilities and market presence.
What is the highest forecasted price for EXEL Exelixis Inc.?
The highest price target for EXEL is $45.00 from David Lebowitz at Citigroup, which represents a 22.8% increase from the current price of $36.65.
What is the lowest forecasted price for EXEL Exelixis Inc.?
The lowest price target for EXEL is $23.00 from Sudan Loganathan at Stephens & Co., which represents a -37.2% decrease from the current price of $36.65.
What is the overall EXEL consensus from analysts for Exelixis Inc.?
The overall analyst consensus for EXEL is bullish. Out of 29 Wall Street analysts, 12 rate it as Buy, 9 as Hold, and 1 as Sell, with a median price target of $38.50.
How accurate are EXEL stock price projections?
Stock price projections, including those for Exelixis Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
